Enter multiple symbols separated by commas

Stocks Gilead Sciences Inc


  • Gilead posts huge beat on earnings and revenue Tuesday, 28 Jul 2015 | 5:28 PM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.

  • July 28- Gilead Sciences Inc said on Tuesday its quarterly net profit rose 32 percent, driven by sales of hepatitis C drugs that beat Wall Street estimates. Looking ahead, Gilead raised its outlook for full-year 2015 product sales by $1 billion to between $29 billion and $30 billion. Excluding items, Gilead earned $3.15 a share in the second quarter, exceeding the...

  • *Focus on corporate results eclipses China worry. *Twitter and Gilead up after the bell; Yelp drops. "The S&P has had five down days in a row and a lot of people are starting to nibble," said Michael Matousek, head trader at U.S. Global Investors Inc in San Antonio, which manages about $1 billion.

  • Top trades to go: Earnings edition Tuesday, 28 Jul 2015 | 1:43 PM ET

    The "Halftime Report" traders give their trades on earnings for the second half.

  • Minefield for market with Fed, earnings, commodities Monday, 27 Jul 2015 | 8:08 AM ET
    An oil trader works on the floor of the New York Mercantile Exchange.

    The Fed meets next week, but a commodities meltdown and earnings season are adding to concerns about global growth and may steal some of its thunder.

  • Cramer game plan—My Fed-pectations in week ahead Friday, 24 Jul 2015 | 6:13 PM ET
    Federal Reserve Board Chair Janet Yellen testifies before a House Financial Services committee hearing on Capitol Hill in Washington, July 15, 2015.

    Jim Cramer lays out his game plan next week. It will all about the Fed, Fed, Fed with a side of China.

  • Battle coming for blockbuster cholesterol drugs Friday, 24 Jul 2015 | 3:59 PM ET
    A Sanofi lab worker packages vaccines.

    One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.

  • July 24- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus infections. The regulator cleared AbbVie Inc's Technivie, which targets HCV genotype 4 infections, and Bristol-Myers Squibb Co's Daklinza, used to treat HCV genotype 3 infections. Technivie, includes the same cocktail of drugs that...

  • *AbbVie CEO sees 2015 Humira growth in mid-teens. July 24 (Reuters)- AbbVie Inc reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sparking concerns over slowing sales growth for its flagship arthritis drug, Humira. AbbVie reported total Humira sales of $3.54 billion for the quarter ended June 30, a 7.6 percent fall from a...

  • Health care takes earnings hot hand into week ahead Friday, 24 Jul 2015 | 10:23 AM ET
    Pfizer headquarters in New York.

    Health-care stocks are batting 12 for 12 in beating earnings estimates. Will the streak last?

  • July 24- AbbVie Inc on Friday reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sending its shares down 3 percent in premarket trading. Deutsche Bank analyst Robyn Karnauskas attributed the revenue miss to smaller-than-expected sales of AbbVie's hepatitis C treatment, Viekira Pak, in the United States.

  • Your first trade for Tuesday Monday, 13 Jul 2015 | 6:32 PM ET

    The "Fast Money" traders give their final trades of the day.

  • 3 more picks from investor up 27% in ‘15 Tuesday, 7 Jul 2015 | 6:00 AM ET
    Monster Beverage

    Louis Navellier's "Squawk Box" Platinum Portfolio is already up 27 percent this year. Here are three of his favorite picks.

  • Your first trade for Wednesday Tuesday, 30 Jun 2015 | 6:21 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Robertson: Euro could easily go below parity Tuesday, 30 Jun 2015 | 5:42 PM ET
    Tiger Management Advisors LLC CEO and co-founder Julian Robertson

    Greece itself isn't terribly important; the problem would be possible contagion if it exits the euro, hedge fund pioneer Julian Robertson said.

  • In their June 25 lawsuit, Yale University's Global Health Justice Partnership and the Treatment Action Group, an AIDS non-profit, said doctors and patients deserve more information about the "enormously costly" drugs Harvoni and Sovaldi to make informed decisions about whether to use them. The plaintiffs said Gilead ignored its request for the trial data,...

  • June 24- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study. All the patients in the study showed a sustained response to Viekira Pak as a standalone treatment after 12 weeks...

  • Biotech to break out, buy these names: Analyst Friday, 19 Jun 2015 | 3:19 PM ET
    Biotech research

    Biotech is going to break out, RBC Capital Markets' Michael Yee said. There are the names on his buy list.

  • Early movers: HSY, RHT, SWHC, STT, CAG & more Friday, 19 Jun 2015 | 7:50 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Gilead still has China patent for active compound. NEW YORK/ SHANGHAI, June 19- China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment. Gilead, however, holds the China patent to the base...